Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?

Clinical Pharmacokinetics

Volumn 50, Issue 7, 2011, Pages 415-428

  Schwenger, Erin ^a   Dumontet, Jane ^a,b   Ensom, Mary H H ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Cottonwood Connolly and Cypress Lodges Fraser Health ^*  (Canada)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Antipsychotics; Drug monitoring; Olanzapine; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DESVENLAFAXINE; DRUG METABOLITE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; GLUCOSE; GLUCURONOSYLTRANSFERASE 1A4; HALOPERIDOL; LITHIUM; NORCLOZAPINE; NORLCLOZAPINE; NOROLANZAPINE; OLANZAPINE; PALIPERIDONE; PLACEBO; PROBENECID; QUETIAPINE; RISPERIDONE; RITONAVIR; SERTINDOLE; TRIMIPRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

ALGORITHM; ALZHEIMER DISEASE; AREA UNDER THE CURVE; BLOOD ANALYSIS; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); CONSTIPATION; DELIRIUM; DEPRESSION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG MONITORING; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG URINE LEVEL; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; GAS CHROMATOGRAPHY; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERPROLACTINEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; NEUROLEPTIC MALIGNANT SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PHARMACOLOGICAL PARAMETERS; PLASMA PROTEIN BINDING; POSTINJECTION DELIRIUM SEDATION SYNDROME; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; QT PROLONGATION; RACE DIFFERENCE; RECEPTOR OCCUPANCY; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; SMOKING CESSATION; TREATMENT DURATION; URINALYSIS; WEIGHT GAIN;

ALGORITHMS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG MONITORING; HUMANS; SCHIZOPHRENIA; TIME FACTORS;

EID: 79958268281     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11587240-000000000-00000     Document Type: Review

References (132)

1. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2004; 161: 1-56.
2. McGlashan TH. A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 1988; 14: 515-42. (Pubitemid 19129692)
3. Dingman CW, McGlashan TH. Discriminating characteristics of suicides: Chestnut Lodge follow-up sample including patients with affective disorder, schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 1986; 74: 91-7. (Pubitemid 16061294)
4. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Arch Gen Psychiatry 1978; 35: 153-5. (Pubitemid 9193590)
5. Hiroeh U, Appleby L, Mortensen PB, et al. Death by homicide, suicide, and other unnatural causes in people with mental illness: a population-based study. Lancet 2001; 358: 2110-2. (Pubitemid 34094900)
6. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000; 45: 21-8.
7. Krausz M, Muller-Thomsen T. Schizophrenia with onset in adolescence: an 11-year followup. Schizophr Bull 1993; 19: 831-41. (Pubitemid 23339439)
8. McGlashan TH, Fenton WS. Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr Bull 1993; 19: 71-84. (Pubitemid 23073556)
9. McGlashan TH, Fenton WS. Classical subtypes for schizophrenia: literature review for DSM-IV. Schizophr Bull 1991; 17: 609-32.
10. McGlashan TH. The prediction of outcome in chronic schizophrenia: IV. The Chestnut Lodge follow-up study. Arch Gen Psychiatry 1986; 43: 167-76. (Pubitemid 16163535)
11. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes: II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 1991; 48: 978-86.
12. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes: I. Longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia. Arch Gen Psychiatry 1991; 48: 969-77.
13. Fenton WS, McGlashan TH. Prognostic scale for chronic schizophrenia. Schizophr Bull 1987; 13: 277-86. (Pubitemid 18039086)
14. Bromet EJ, Fennig S. Epidemiology and natural history of schizophrenia. Biol Psychiatry 1999; 46: 871-81. (Pubitemid 29452978)
15. Bardenstein KK, McGlashan TH. Sex differences in affective, schizoaffective, and schizophrenic disorders: a review. Schizophr Res 1990; 3: 159-72. (Pubitemid 20157294)
16. National Collaborating Centre for Mental Health. Schizophrenia: the NICE guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care [national clinical guideline number 82; online] Available from URL: http://www.nice.org.uk/niceme dia/live/11786/43607/ 43607.pdf [Accessed 2011 Apr 5].
17. Baumann P, Hiemke C, Ulrich S, et al.; Arbeitsgemeinschaft fü r Neuropsychopharmakologie und Pharmakopsychiatrie. The AGNP-TDM Expert Group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-65.
18. American Psychiatric Association. Guideline watch (September 2009): practice guideline for the treatment of patients with schizophrenia [online]. Available from URL: http://www.psychiatryonline.com/pracGuide/prac GuideTopic-6.aspx [Accessed 2011 Apr 5].
19. Ensom MH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes? Clin Pharmacokinet 1998; 34: 265-79. (Pubitemid 28162184)
20. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia [published erratum appears in N Engl J Med 2010; 363: 1092-3]. N Engl J Med 2005; 353: 1209-23.
21. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006; 63: 1079-87.
22. Kahn RS, Fleischhacker WW, Boter H, et al.; EUFEST Study Group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371: 1085-97. (Pubitemid 351418005)
23. Boter H, Peuskens J, Libiger J, et al.; EUFEST Study Group. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res 2009; 115: 97-103.
24. Kasper S, Winkler D. Addressing the limitations of the CATIE study. World J Biol Psychiatry 2006; 7: 126-7. (Pubitemid 43738912)
25. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009; 39: 1591-602.
26. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 2009; 23: 649-59.
27. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
28. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-tohead comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 152-63.
29. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-6.
30. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of secondgeneration antipsychotics. Arch Gen Psychiatry 2003; 60: 553-64.
31. Adams CE, Jayaram M. Do findings from new trials for schizophrenia fit with existing evidence: not dupedyjust beguiled? Epidemiol Psychiatr Soc 2007; 16: 199-202. (Pubitemid 47546904)
32. Haro JM, Novick D, Suarez D, et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006; 26: 571-8. (Pubitemid 44772733)
33. Duggan L, Fenton M, Rathbone J, et al. Olanzapine for schizophrenia. Cochrane Database Syst Rev 2005; (2): CD001359.
34. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.AmJ Psychiatry 2001; 158: 1149-51. (Pubitemid 32623122)
35. Wright P, Lindborg SR, Birkett M, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry 2003; 48: 716-21. (Pubitemid 38197030)
36. Lindborg SR, Beasley CM, Alaka K, et al. Effects of intramuscular olanzapine vs haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Res 2003; 119: 113-23. (Pubitemid 36829423)
37. de la Torre SC, Martinez MA, Almarza E. Determination of several psychiatric drugs in whole blood using capillary gas-liquid chromatography with nitrogen phosphorus detection: comparison of two solid phase extraction procedures. Forensic Sci Int 2005; 155: 193-204. (Pubitemid 41454958)
38. Ulrich S. Assay of olanzapine in human plasma by a rapid and sensitive gas chromatography-nitrogen phosphorus selective detection (GC-NPD) method: validation and comparison with high-performance liquid chromatography- coulometric detection. Ther Drug Monit 2005; 27: 463-8. (Pubitemid 41098821)
39. BernaM, Shugert R, Mullen J. Determination of olanzapine in human plasma and serum by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 1998; 33: 1003-8. (Pubitemid 28499669)
40. Berna M, Ackermann B, Ruterbories K, et al. Determination of olanzapine in human blood by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 767: 163-8. (Pubitemid 34142348)
41. Bogusz MJ, Kruger KD, Maier RD, et al. Monitoring of olanzapine in serum by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 1999; 732: 257-69. (Pubitemid 29460841)
42. Chin C, Zhang ZP, Karnes HT. A study of matrix effects on an LC/MS/MS assay for olanzapine and desmethyl olanzapine. J Pharm Biomed Anal 2004; 35: 1149-67. (Pubitemid 39140281)
43. Gervasini G, Vizcaino S, Herraiz AG, et al. Applicability of an assay for routine monitoring of highly variable concentrations of olanzapine based on HPLC with mass spectrometric detection. Clin Chem 2003; 49: 2088-91. (Pubitemid 37449485)
44. Nirogi RV, Kandikere VN, Shukla M, et al. Development and validation of a sensitive liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma. J Pharm Biomed Anal 2006; 41: 935-42.
45. Josefsson M, Kronstrand R, Andersson J, et al. Evaluation of electrospray ionisation liquid chromatography-tandem mass spectrometry for rational determination of a number of neuroleptics and their major metabolites in human body fluids and tissues. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 789: 151-67. (Pubitemid 36513796)
46. JosefssonM,Roman M, Skogh E, et al. Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid. J Pharm Biomed Anal 2010; 53: 576-82.
47. Kirchherr H, Kuhn-Velten WN. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 843: 100-13. (Pubitemid 44512257)
48. Choong E, Rudaz S, Kottelat A, et al. Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. J Pharm Biomed Anal 2009; 50: 1000-8.
49. Zhou Z, Li X, Li K, et al. Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 802: 257-62. (Pubitemid 38264450)
50. Nielsen MK, Johansen SS.Determination of olanzapine in whole blood using simple protein precipitation and liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2009; 33: 212-7.
51. Saar E, Gerostamoulos D, Dummer OH, et al. Identification and quantification of 30 antipsychotics in blood using LC-MS/MS. J Mass Spectrom 2010; 45: 915-25.
52. Dusci LJ, Peter Hackett L, Fellows LM, et al. Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 773: 191-7. (Pubitemid 34595392)
53. D'Arrigo C, Migliardi G, Santoro V, et al. Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 2006; 28: 388-93. (Pubitemid 44314927)
54. Boulton DW, Markowitz JS, DeVane CL. A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. J Chromatogr B Biomed Sci Appl 2001; 759: 319-23. (Pubitemid 32575292)
55. Olesen OV, Poulsen B, Linnet K. Fully automated on-line determination of olanzapine in serum for routine therapeutic drug monitoring. Ther Drug Monit 2001; 23: 51-5. (Pubitemid 32105965)
56. Kollroser M, Schober C. Direct-injection high performance liquid chromatography ion trap mass spectrometry for the quantitative determination of olanzapine, clozapine and N-desmethylclozapine in human plasma. Rapid Commun Mass Spectrom 2002; 16: 1266-72. (Pubitemid 34717252)
57. Sachse J, Koller J, Hartter S, et al. Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 830: 342-8. (Pubitemid 43075471)
58. Sabbioni C, Saracino MA, Mandrioli R, et al. Rapid analysis of olanzapine and desmethylolanzapine in human plasma using high-performance liquid chromatography with coulometric detection. Anal Chim Acta 2004; 516: 111-7. (Pubitemid 38813103)
59. Aravagiri M, Ames D, Wirshing WC, et al. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. Ther Drug Monit 1997; 19: 307-13. (Pubitemid 28053486)
60. Raggi MA, Casamenti G, Mandrioli R, et al. A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure. J Chromatogr B Biomed Sci Appl 2001; 750: 137-46. (Pubitemid 33648338)
61. Catlow JT, Barton RD, Clemens M, et al. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1995; 668: 85-90.
62. Llorca PM, Coudore F, Corpelet C, et al. Integration of olanzapine determinations in a HPLC-diode array detection system for routine psychotropic drug monitoring. Clin Chem 2001; 47: 1719-21. (Pubitemid 32781595)
63. Titier K, Bouchet S, Pehourcq F, et al. High-performance liquid chromatographic method with diode array detection to identify and quantify atypical antipsychotics and haloperidol in plasma after overdose. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 788: 179-85. (Pubitemid 36369121)
64. Sturm S, Hammann F, Drewe J, et al. An automated screening method for drugs and toxic compounds in human serum and urine liquid chromatography- tandem mass spectrometry. J Chromatogr B 2010; 878: 2726-32.
65. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res 1999; 40: 101-4. (Pubitemid 29494233)
66. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, sex, smoking, and comedication. Ther Drug Monit 2003; 25: 46-53. (Pubitemid 36139825)
67. Perry PJ, Lund BC, Sanger T, et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 2001; 21: 14-20. (Pubitemid 32096745)
68. Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit 1999; 21: 87-90. (Pubitemid 29077459)
69. Bergemann N, Frick A, Parzer P, et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry 2004; 37: 63-8. (Pubitemid 38651019)
70. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007; 46: 359-88. (Pubitemid 46686464)
71. Mauri MC, Steinhilber CP, Marino R, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry 2005; 20: 55-60. (Pubitemid 40092392)
72. Nozawa M, Ohnuma T, Matsubara Y, et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit 2008; 30: 35-40. (Pubitemid 351161096)
73. RobertsonMD, McMullin MM. Olanzapine concentrations in clinical serum and postmortem blood specimens: when does therapeutic become toxic? J Forensic Sci 2000; 45: 418-21. (Pubitemid 30158420)
74. Skogh E, Sjodin I, Josefsson M, et al. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J Clin Psychopharmacol 2011; 31: 4-9.
75. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998; 155: 921-8. (Pubitemid 28307604)
76. Harvey EJ, Taylor DM, Flanagan RJ. D2 receptor occupancy under recommended and high doses of olanzapine. J Psychopharmacol 2001; 15: 213-4. (Pubitemid 32808258)
77. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol 1997; 17: 472-7. (Pubitemid 28389187)
78. Fellows L, Ahmad F, Castle DJ, et al. Investigation of target plasma concentration- effect relationships for olanzapine in schizophrenia. Ther Drug Monit 2003; 25: 682-9. (Pubitemid 37499302)
79. Citrome L, Stauffer VL, Chen L, et al. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol 2009; 29: 278-83.
80. Kelly DL, Richardson CM, Yu Y, et al. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol 2006; 21: 393-8. (Pubitemid 44355618)
81. Lane HY, Guo SC, Hwang TJ, et al. Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study. J Clin Psychopharmacol 2002; 22: 530-2.
82. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76. (Pubitemid 18039085)
83. Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33: 766-71.
84. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812.
85. Haro J, Kamath S, Ochoa S, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 2003; 107: 16-23.
86. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21: 911-36. (Pubitemid 47557106)
87. Chew ML, Mulsant BH, Pollock BG, et al.Amodel of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006; 88: 63-72. (Pubitemid 44693242)
88. Ramaswamy K, Kozma CM, Nasrallah H. Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine. Drug Saf 2007; 30: 589-99. (Pubitemid 47037318)
89. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-35.
90. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004; 64: 701-23. (Pubitemid 38471372)
91. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician 2010; 81: 617-22.
92. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68 (Suppl. 1): 20-7.
93. Johnson V, Bruxner G. Neuroleptic malignant syndrome associated with olanzapine. Aust N Z J Psychiatry 1998; 32: 884-6. (Pubitemid 29086132)
94. Bobes J, Garc A-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003; 29: 125-47. (Pubitemid 36278732)
95. Skogh E, Reis M, Dahl ML, et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 2002; 24: 518-26. (Pubitemid 34857906)
96. Perry PJ, Argo TR, Carnahan RM, et al. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol 2005; 25: 250-4. (Pubitemid 40685789)
97. O'Malley GF, Seifert S, Heard K, et al. Olanzapine overdose mimicking opioid intoxication. Ann Emerg Med 1999; 34: 279-81. (Pubitemid 29361880)
98. CapelMM,Colbridge MG, Henry JA. Overdose profiles of new antipsychotic agents. Int J Neuropsychopharmacol 2000; 3: 51-4. (Pubitemid 30354452)
99. Bond GR, Thompson JD. Olanzapine pediatric overdose. Ann Emerg Med 1999; 34: 292-3.
100. Cohen LG, Fatalo A, Thompson BT, et al. Olanzapine overdose with serum concentrations. Ann Emerg Med 1999; 34: 275-8. (Pubitemid 29361879)
101. Stephens BG, Coleman DE, Baselt RC. Olanzapine-related fatality. J Forensic Sci 1998; 43: 1252-3. (Pubitemid 28554830)
102. Trenton A, Currier G, Zwemer F. Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs 2003; 17: 307-24. (Pubitemid 36469970)
103. Lennestal R, Asplund C,NilssonM, et al. Serum levels of olanzapine in a nonfatal overdose. J Anal Toxicol 2007; 31: 119-21. (Pubitemid 46557485)
104. Elian AA. Fatal overdose of olanzepine. Forensic Sci Int 1998; 91: 231-5. (Pubitemid 28105405)
105. Gerber JE, Cawthon B. Overdose and death with olanzapine: two case reports. Am J Forensic Med Pathol 2000; 21: 249-51. (Pubitemid 30667074)
106. Chue P, Singer P. A review of olanzapine-associated toxicity and fatality in overdose. J Psychiatry Neurosci 2003; 28: 253-61. (Pubitemid 37153434)
107. Bosch RF, Baumbach A, Bitzer M, et al. Intoxication with olanzapine. Am J Psychiatry 2000; 157: 304-5.
108. Attarbaschi T, Sacher J, Geiss-Granadia T, et al. Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine. Eur Neuropsychopharmacol 2007; 17: 102-7. (Pubitemid 44802834)
109. McDonnell D, Detke H, Bergstrom R, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection: II. Investigations of mechanism. BMC Psychiatry 2010; 10: 45.
110. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37: 177-93. (Pubitemid 29452754)
111. Callaghan JT, Cerimele BJ, Kassahun KJ, et al. Olanzapine: interaction study with imipramine. J Clin Pharmacol 1997; 37: 971-8. (Pubitemid 27514916)
112. Shirley KL, Hon YY, Penzak SR, et al. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology 2003; 28: 961-6.
113. Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008; 48: 157-65.
114. Bachmann CJ, Haberhausen M, Heinzel-Gutenbrunner M, et al. Large intraindividual variability of olanzapine serum concentrations in adolescent patients. Ther Drug Monit 2008; 30: 108-12. (Pubitemid 351161108)
115. Darby JK, Pasta DJ, Wilson MG, et al. Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study. Clin Drug Investig 2008; 28: 553-64.
116. Carrillo JA, Herraiz AG, Ramos SI, et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23: 119-27. (Pubitemid 36368788)
117. Chiu CC, Lu ML, Huang MC, et al. Heavy smoking, reduced olanzapine levels, and treatment effects: a case report. Ther Drug Monit 2004; 26: 579-81.
118. Haslemo T, Eikeseth PH, Tanum L, et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 2006; 62: 1049-53. (Pubitemid 44786497)
119. Wu TH, Chiu CC, Shen WW, et al. Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1889-93.
120. Hagg S, Spigset O, Lakso HA, et al. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol 2001; 57: 493-7.
121. Weiss U, Marksteiner J, Kemmler G, et al. Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol 2005; 25: 570-4. (Pubitemid 41669052)
122. Sathirakul K, Chan C, Teng L, et al. Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects. Br J Clin Pharmacol 2003; 56: 184-7. (Pubitemid 36981433)
123. Baghdady NT, Banik S, Swartz SA, et al. Psychotropic drugs and renal failure: translating the evidence for clinical practice. Adv Ther 2009; 26: 404-24.
124. Eli Lilly and Company. Zyprexa (olanzapine): US prescribing information [online]. Available from URL: http://pi.lilly.com/us/zyprexa-pi.pdf [Accessed 2011 Apr 5].
125. Chiu CC, Lane HY, Huang MC, et al. Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol 2004; 44: 1385-90.
126. Hiemke C, Peled A, Jabarin M, et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 2002; 22: 502-6.
127. Wang CY, Zhang ZJ, Li WB, et al. The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. J Clin Pharmacol 2004; 44: 785-92.
128. Weigmann H, Gerek S, Zeisig A, et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 2001; 23: 410-3. (Pubitemid 32708927)
129. Markowitz JS, Devane CL, Liston HL, et al. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. Clin Pharmacol Ther 2002; 71: 30-8. (Pubitemid 34124036)
130. Penzak SR, Hon YY, Lawhorn WD, et al. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol 2002; 22: 366-70. (Pubitemid 34810325)
131. Gossen D, de Suray JM, Vandenhende F, et al. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 2002; 4: E11.
132. Welden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419-29